Trial Profile

A Multicenter, Open-label, Randomized Phase 2b Clinical Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Patients With Chronic Hepatitis Delta

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bulevirtide (Primary) ; Peginterferon alfa-2a
Indications Hepatitis D
Focus Registrational; Therapeutic Use
Sponsors Gilead Sciences; MYR Pharma

Most Recent Events

06 Jun 2024 According to a Gilead Sciences media release, data from this study presented at the European Association for the Study of the Liver (EASL) Congress
06 Jun 2024 According to a Gilead Sciences media release, data from this study published the New England Journal of Medicine (NEJM)
06 Jun 2024 Results published in the Gilead Sciences Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com